{"id":"https://openalex.org/W1960009902","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2015","title":"Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: Initial report of the EORTC study 26061","display_name":"Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: Initial report of the EORTC study 26061","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W1960009902","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2015","mag":"1960009902"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.2015","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2015","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.2015","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053052330","display_name":"Roger Stupp","orcid":"https://orcid.org/0000-0002-5483-3118","observed_orcids":["https://orcid.org/0000-0002-5483-3118"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Stupp","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019091770","display_name":"A. Tosoni","orcid":"https://orcid.org/0000-0001-9004-2623","observed_orcids":["https://orcid.org/0000-0001-9004-2623"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Tosoni","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026126995","display_name":"Walter Taal","orcid":"https://orcid.org/0000-0002-5530-7259","observed_orcids":["https://orcid.org/0000-0002-5530-7259"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Taal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039810007","display_name":"Peter Hau","orcid":"https://orcid.org/0000-0003-3894-5053","observed_orcids":["https://orcid.org/0000-0003-3894-5053"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Hau","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071553983","display_name":"Mario Campone","orcid":"https://orcid.org/0000-0002-5196-5908","observed_orcids":["https://orcid.org/0000-0002-5196-5908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Campone","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012753378","display_name":"Johanna M. M. Gijtenbeek","orcid":"https://orcid.org/0000-0002-0844-7259","observed_orcids":["https://orcid.org/0000-0002-0844-7259"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Gijtenbeek","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001307415","display_name":"Marc Fr\u00e9nay","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. P. Frenay","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038129366","display_name":"Thierry Gorlia","orcid":"https://orcid.org/0009-0009-9159-2761","observed_orcids":["https://orcid.org/0009-0009-9159-2761"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Gorlia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103260191","display_name":"Denis Lacombe","orcid":"https://orcid.org/0000-0003-1128-155X","observed_orcids":["https://orcid.org/0000-0003-1128-155X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Lacombe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5087336206","display_name":"Alba Ariela Brandes","orcid":"https://orcid.org/0000-0002-2503-9089","observed_orcids":["https://orcid.org/0000-0002-2503-9089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. A. Brandes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"2015","last_page":"2015"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sagopilone","display_name":"sagopilone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/epothilone-analogs","display_name":"epothilone analogs","score":0.8759999871253967},{"id":"https://openalex.org/keywords/recurrent-glioblastoma","display_name":"recurrent glioblastoma","score":0.9959999918937683},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.765999972820282},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.43799999356269836},{"id":"https://openalex.org/keywords/p-glycoprotein","display_name":"P-glycoprotein","score":0.3659999966621399},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.36899998784065247},{"id":"https://openalex.org/keywords/stable-disease","display_name":"stable disease","score":0.4819999933242798},{"id":"https://openalex.org/keywords/neuropathy","display_name":"neuropathy","score":0.5960000157356262},{"id":"https://openalex.org/keywords/leukopenia","display_name":"leukopenia","score":0.7509999871253967},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8100000023841858},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.7089999914169312}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9238610863685608},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6326818466186523},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5964443683624268},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.48536908626556396},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4688830077648163},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.46087104082107544},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.45139217376708984},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.4428228437900543},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.43436992168426514},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.42924758791923523},{"id":"https://openalex.org/C2910384678","wikidata":"https://www.wikidata.org/wiki/Q6744211","display_name":"Mallinckrodt","level":2,"score":0.42291003465652466},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.41870713233947754},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.41782858967781067},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4155632257461548},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.41454747319221497},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.41442155838012695},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40114402770996094},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3772294521331787},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.35055553913116455},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.295033723115921},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.26188546419143677},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.2015","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2015","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.2015","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:epub.uni-regensburg.de:68134","doi":null,"is_oa":false,"landing_page_url":"https://epub.uni-regensburg.de/68134/","pdf_url":null,"source":{"id":"https://openalex.org/S4306401229","display_name":"University of Regensburg Publication Server (University of Regensburg)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I60668342","host_organization_name":"University of Regensburg","host_organization_lineage":["https://openalex.org/I60668342"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2154429953","https://openalex.org/W2302052030","https://openalex.org/W1971423558","https://openalex.org/W2322177564","https://openalex.org/W2020369220","https://openalex.org/W2412426552","https://openalex.org/W174783431","https://openalex.org/W1974930851","https://openalex.org/W2057291610","https://openalex.org/W2115037148"],"abstract_inverted_index":{"2015":[0],"Background:":[1],"Sagopilone":[2,114],"is":[3,30,72,281,288,295],"a":[4,21,61],"fully":[5],"synthetic":[6],"analog":[7],"of":[8,52,63,92,207,257,324,345],"epothilone":[9],"B.":[10],"It":[11],"inhibits":[12],"microtubule":[13],"depolarization":[14],"and":[15,106,110,170,199,245,255,310,329],"induces":[16],"cell":[17],"cycle":[18],"arrest.":[19],"Not":[20],"substrate":[22],"for":[23,218],"ABCB1,":[24],"good":[25],"penetration":[26],"into":[27],"normal":[28],"brain":[29,35],"expected.":[31],"In":[32],"orthotopically":[33],"implanted":[34],"tumor":[36],"models":[37],"it":[38],"has":[39,336],"demonstrated":[40],"antitumor":[41],"activity.":[42],"This":[43,334],"early":[44],"clinical":[45],"trial":[46,335],"aims":[47],"at":[48,68,326],"evaluating":[49],"the":[50,57,73,90,158,292,314],"efficacy":[51],"sagopilone":[53,325],"in":[54,154,164,191,196,202,224,253,277,331,339],"recurrent":[55],"glioblastoma,":[56],"success":[58,142,146,286],"rate":[59,287],"as":[60,118,270],"composite":[62],"response":[64,262],"or":[65,82],"progression-free":[66],"survival":[67],"6":[69,203],"months":[70],"[PFS-6]":[71],"primary":[74],"endpoint.":[75],"Methods:":[76],"Pts":[77],"with":[78],"measurable":[79],"first":[80],"recurrence":[81],"progressive":[83],"disease":[84,222,268],"after":[85],"\u2265":[86,149],"3":[87,119,123],"mo":[88],"from":[89,177],"end":[91],"radiochemotherapy":[93],"were":[94,152,180,210],"eligible,":[95],"if":[96,148],"WHO":[97],"performance":[98],"status":[99],"[PS]":[100],"\u2264":[101],"2,":[102,213],"no":[103],"significant":[104,351],"co-morbidity":[105],"adequate":[107],"hematological,":[108],"liver":[109],"renal":[111],"function":[112],"tests.":[113],"(16mg/m\u00b2)":[115],"was":[116,126,137,189,221,250,263],"administered":[117,211],"h":[120],"infusion":[121],"every":[122,128],"wks.":[124],"Response":[125],"assessed":[127],"2":[129,201,247,278],"cycles":[130,209],"(6":[131],"wks).":[132],"Fleming's":[133],"one":[134],"stage":[135],"design":[136],"selected":[138],"assuming:":[139],"P0,":[140],"unacceptable":[141],"rate=8%;":[143],"P1,":[144],"target":[145],"rate=23%;":[147],"5":[150],"successes":[151],"observed":[153],"35":[155],"evaluable":[156],"pts,":[157,193,258],"drug":[159],"would":[160],"be":[161,307],"considered":[162],"interesting":[163],"this":[165,327],"indication.":[166],"Results:":[167],"Between":[168],"12/2006":[169],"08/2007,":[171],"38":[172],"(36":[173],"eligible":[174],"treated)":[175],"pts":[176,198,266,274,279],"7":[178],"institutions":[179],"enrolled:":[181],"median":[182],"age":[183],"57":[184],"yrs":[185],"(range":[186],"20\u201376),":[187],"PS":[188,194,200],"0":[190],"14":[192],"1":[195,244],"17":[197],"pts.":[204],"A":[205],"total":[206],"100":[208],"(median":[212],"range":[214],"1\u20136),":[215],"main":[216,315],"reason":[217],"treatment":[219],"discontinuation":[220],"progression":[223],"82%.":[225],"Related":[226],"toxicity":[227,249],"(grade":[228],"3)":[229],"was:":[230],"leucopenia":[231],"(2":[232,238],"pts),":[233,236,239],"neutropenia":[234],"(3":[235],"fatigue":[237],"neuropathy":[240],"(1":[241],"pt).":[242],"Grade":[243],"grade":[246],"neuro-sensory":[248],"also":[251],"reported":[252],"35%":[254],"5%":[256],"respectively.":[259],"No":[260,350],"objective":[261],"documented,":[264],"13":[265],"had":[267],"stabilization":[269],"best":[271],"response.":[272],"Two":[273],"achieved":[275],"PFS-6,":[276],"follow-up":[280],"too":[282],"early.":[283],"The":[284,301],"current":[285],"5.7%,":[289],"(95%CI":[290],"0.007\u201319.0),":[291],"actuarial":[293],"PFS-6":[294],"9.4%":[296],"(95%":[297],"CI":[298],"2.5\u201322.0).":[299],"Conclusions:":[300],"envisaged":[302],"activity":[303],"mark":[304],"can":[305],"not":[306,320],"reached.":[308],"Hematotoxicity":[309],"neurosensory":[311],"alterations":[312],"are":[313],"toxicities.":[316],"Our":[317],"results":[318],"do":[319],"support":[321],"further":[322],"exploration":[323],"dose":[328],"schedule":[330],"malignant":[332],"glioma.":[333],"been":[337],"supported":[338],"part":[340],"by":[341],"an":[342],"unrestricted":[343],"grant":[344],"Bayer-Schering":[346],"Pharma,":[347],"Berlin,":[348],"Germany.":[349],"financial":[352],"relationships":[353],"to":[354],"disclose.":[355]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}